Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
about
Potential use of rapamycin in HIV infectionExpanding the antimalarial toolkit: Targeting host-parasite interactionsConjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its actionWillingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in ChinaCellular Responses and Tissue Depots for Nanoformulated Antiretroviral TherapyHIV-1 induces cytoskeletal alterations and Rac1 activation during monocyte-blood-brain barrier interactions: modulatory role of CCR5Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.Interactions between alcohol and the HIV entry inhibitor Maraviroc.Singlet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors.Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study.In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.Co-receptor usage and prediction of V3 genotyping algorithms in HIV-1 subtype B' from paid blood donors experienced anti-retroviral therapy in Chinese central province.Antiviral drugs specific for coronaviruses in preclinical developmentInhibition of infection-mediated preterm birth by administration of broad spectrum chemokine inhibitor in mice.The impact of HIV-1 on neurogenesis: implications for HANDMaraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanismsClinical use of CCR5 inhibitors in HIV and beyondBasigin is a druggable target for host-oriented antimalarial interventions.Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variantsFatigue-induced Orosomucoid 1 Acts on C-C Chemokine Receptor Type 5 to Enhance Muscle EnduranceCCR6 as a possible therapeutic target in psoriasis.Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs.HIV interactions with monocytes and dendritic cells: viral latency and reservoirs.Genetics and the general physician: insights, applications and future challenges.The future of HIV microbicides: challenges and opportunities.Chemokine receptor antagonists: part 2.Role of CCR5 Delta32 bp deletion in RA and SLE.Pharmacogenetics in reproductive and perinatal medicine.Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure.Potential of polymeric nanoparticles in AIDS treatment and prevention.Targeting chemokine receptors in allergic disease.Immunomodulation using agonists and antagonists: potential clinical applications.Targeting CCR5 for anti-HIV research.Allosteric therapies for lung cancer.Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
P2860
Q24606795-8C0E34F8-0C1E-4CD4-BB3E-489C2B19BF6FQ26772866-2BD899A9-85B3-444F-B9CD-AEF725C6C03EQ28485911-03138FC8-64E4-4164-A440-23DB3D305752Q28544731-3E04377D-480E-4F88-A355-7DBCD03F1624Q28551873-F51DEE37-FF12-4831-8608-ECFBCB7D6DE0Q33588957-D96E349A-2B7C-449D-AE34-EAFE6355D28DQ33784852-29BEB605-4873-4FF3-B165-9228AF9AE1EFQ33909050-36AA059C-F9C3-4A0C-B3B1-14F88752C15DQ34039661-811830A7-ED9B-4BA1-9D4C-9B4AB67135AFQ34057606-41165423-C89D-4142-B7F7-4742CE1AA898Q34103125-7FBB8718-8E8C-4554-8D6B-0148FDEADAAEQ34332104-31432081-A6A2-4DB6-8627-0C0A087E0375Q34332580-D64B7AA1-CDF3-4B0B-85DE-47B60D481595Q34336857-5B3AAB53-8317-4259-B97C-359648455D25Q34472345-917213D3-3C1D-4D2D-83FD-2DFDC499EDE5Q34604941-FA596115-E598-4608-8996-F1E14E895F70Q34725136-4EE157C4-F163-4F90-A67E-2E0904742FF6Q35018145-F662DC82-2216-48B6-8043-26E1EB5C6F24Q35894355-93316FBF-3E74-4832-BA60-ED75089B16AEQ36084912-7E95D024-83F1-4B25-84FD-BF988ABA224BQ36185528-FA9654F0-0ABB-4FFD-8631-01EE8233E8C8Q36438411-274E1E14-10D4-49D3-B90B-C13071201A3DQ36980670-E3B9F45D-12DB-47D7-87C7-7A7B49151BACQ37078995-9DAA5F76-F959-482C-9CDB-7EBC10AA0386Q37229398-C6CD1AF9-3D1C-44C5-9F9A-B7F11FB5E9BEQ37396981-A161263A-7A2C-4909-9C79-D374EFB0F3E4Q37448790-FD1016FD-FBC2-4FE7-A3AA-C188612EA007Q37481304-A7854FD0-1A04-4AF0-B1F7-AFCA264AADECQ37610419-C1B63CDA-5004-4A98-827B-251186274527Q37657531-A2D05319-FA74-472D-9D82-1C93D48AAAC5Q37688270-B72B2390-CEFC-43BE-8AB1-EDBB8C0FD652Q37818325-C5901037-B3BE-4CB4-ACE7-F2D3D78D02E7Q37832529-3E10319A-A05E-4F6B-8FD4-32F6BD4B9393Q37965728-703FEE82-04E6-448E-8B2C-995902C447D6Q38229805-63C86E95-16BA-4D9E-B513-602F07ED28C3Q38465098-998B1755-3275-4F44-A0F7-BA56C961CB4CQ38684463-2F0DB9D1-0AF5-403E-AFF0-93B3762EDC9AQ38803127-021D8881-6188-47CE-90A3-9D357C86783BQ38816965-DC541212-9393-49E4-8DAD-04230FD1BBE4Q38816992-EE49FFA6-0005-4869-B48D-286732972DD0
P2860
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
@ast
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
@en
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
@nl
type
label
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
@ast
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
@en
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
@nl
prefLabel
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
@ast
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
@en
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
@nl
P2093
P1476
Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
@en
P2093
Horatio B Fung
Juan C Bandres
Sharon S Lieberman-Blum
P304
P356
10.1016/S0149-2918(08)80048-3
P577
2008-07-01T00:00:00Z